Sunday 11 October 2026
Export all ABBV data to Excel Powerpack
AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
276.47
4.05
+1.49%
Follow ABBV
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
135.25% | 6,155.88% | (139.61%) | (208.10%) | |
Piotroski F-Score |
7 | 8 | 5 | 7 | |
| 1.69% | 3.11% | 2.64% | 4.61% | ||
ROIC |
9.34% | 15.96% | 16.85% | 18.07% | |
Return on Tangible Assets |
(43.73%) | (48.68%) | (124.65%) | (288.01%) | |
Average Days of Receivables |
78.14 | 75.13 | 72.51 | 78.37 | |
Free Cash Flow per Share |
11.13 | 10.07 | 11.29 | 10.29 | |
Free Cash Flow |
19,684.00 | 17,816.00 | 19,980.00 | 18,210.00 | |
Capital Expenditures |
(1,176.00) | (1,214.00) | (1,244.00) | (1,297.00) | |
| Other line items | |||||
Cash ROIC |
27.41% | 25.64% | 26.42% | 25.47% | |
Accounts Receivable Turnover |
4.92 | 5.20 | 5.03 | 4.87 | |
Accounts Payable Turnover |
0.56 | 0.55 | 0.57 | 0.56 | |
Inventory Turnover |
3.84 | 3.99 | 3.85 | 3.64 | |
Average Days of Payables |
679.91 | 696.44 | 669.25 | 661.85 | |
Days of Inventory on Hand |
99.87 | 99.27 | 100.05 | 101.90 | |
Tax Rate |
0.44 | (0.36) | (0.39) | (0.27) | |
Research and Development Expense of Revenue |
22.28% | 14.87% | 15.12% | 15.09% | |
Selling, General and Administrative Expense of Revenue |
23.42% | 22.91% | 22.76% | 22.79% | |
Share Based Compensation of Revenue |
1.61% | 1.56% | 1.57% | 1.52% | |
Interest Coverage |
3.50 | 5.74 | 5.80 | 6.38 | |
Operating CF/Net income |
8.88 | 4.55 | 5.90 | 3.11 | |
Depreciation/Fixed assets |
2.48 | 1.60 | 1.56 | 1.50 | |
Capex/Depreciation |
(0.09) | (0.14) | (0.14) | (0.15) | |
Revenue per Share |
33.72 | 34.57 | 35.49 | 36.40 | |
Operating CF per Share |
11.79 | 10.76 | 11.99 | 11.03 | |
Capex per Share |
(0.66) | (0.69) | (0.70) | (0.73) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 |
Columns are period end dates